{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T16:30:13Z","timestamp":1746894613681},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T00:00:00Z","timestamp":1497312000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s12185-017-2274-5","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T03:44:04Z","timestamp":1497325444000},"page":"533-540","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of prophylactic irradiation to the contralateral testis for patients with advanced-stage primary testicular lymphoma: an analysis of outcomes at a single institution"],"prefix":"10.1007","volume":"106","author":[{"given":"Ryouji","family":"Tokiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisaku","family":"Yoden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Kamitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Hiratsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Koresawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuminori","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideho","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,13]]},"reference":[{"key":"2274_CR1","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO.2010.31.4187","volume":"29","author":"U Vitolo","year":"2011","unstructured":"Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29:2766\u201372.","journal-title":"J Clin Oncol"},{"key":"2274_CR2","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1200\/JCO.2009.22.5896","volume":"27","author":"JD Gundrum","year":"2009","unstructured":"Gundrum JD, Mathiason MA, Moore DB, Go RS. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009;27:5227\u201332.","journal-title":"J Clin Oncol"},{"key":"2274_CR3","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/0959-8049(94)00311-R","volume":"30A","author":"MB Moller","year":"1994","unstructured":"Moller MB, d\u2019Amore F, Christensen BE. Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis. The Danish Lymphoma Study Group, LYFO. Eur J Cancer. 1994;30A:1760\u20134.","journal-title":"Eur J Cancer"},{"key":"2274_CR4","first-page":"259","volume":"26","author":"N Shahab","year":"1999","unstructured":"Shahab N, Doll DC. Testicular lymphoma. Semin Oncol. 1999;26:259\u201369.","journal-title":"Semin Oncol"},{"key":"2274_CR5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1023\/A:1008282818705","volume":"8","author":"E Zucca","year":"1997","unstructured":"Zucca E, Roggero E, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin\u2019s lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol. 1997;8:727\u201337.","journal-title":"Ann Oncol"},{"key":"2274_CR6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0167-8140(93)90128-U","volume":"27","author":"AM Crellin","year":"1993","unstructured":"Crellin AM, Hudson BV, Bennett MH, Harland S, Hudson GV. Non-Hodgkin\u2019s lymphoma of the testis. Radiother Oncol. 1993;27:99\u2013106.","journal-title":"Radiother Oncol"},{"key":"2274_CR7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<154::AID-CNCR21>3.0.CO;2-T","volume":"88","author":"R Fonseca","year":"2000","unstructured":"Fonseca R, Habermann TM, Colgan JP, O\u2019Neill BP, White WL, Witzig TE, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer. 2000;88:154\u201361.","journal-title":"Cancer"},{"key":"2274_CR8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12185-013-1261-8","volume":"97","author":"C Wang","year":"2013","unstructured":"Wang C, Wang H, Wang Q, Shi B. Primary testicular lymphoma: experience with 13 cases and literature review. Int J Hematol. 2013;97:240\u20135.","journal-title":"Int J Hematol"},{"issue":"5","key":"2274_CR9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.clon.2012.02.005","volume":"24","author":"SS Ahmad","year":"2012","unstructured":"Ahmad SS, Idris SF, Follows GA, Williams MV. Primary testicular lymphoma. Clin Oncol. 2012;24(5):358\u201365.","journal-title":"Clin Oncol"},{"key":"2274_CR10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2003.11.141","volume":"21","author":"E Zucca","year":"2003","unstructured":"Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21:20\u20137.","journal-title":"J Clin Oncol"},{"key":"2274_CR11","unstructured":"Guideline of a radiation treatment planning. Japanese Society for Therapeutic Radiology and Oncology, version 3. 20 Nov 2012."},{"key":"2274_CR12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/leu.2015.237","volume":"30","author":"L Deng","year":"2016","unstructured":"Deng L, Xu-Monette ZY, Loghavi S, Manyam GC, Xia Y, Visco C, et al. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia. 2016;30:361\u201372.","journal-title":"Leukemia"},{"issue":"1","key":"2274_CR13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","volume":"47","author":"Common toxicity criteria, version 2.0","year":"2000","unstructured":"Common toxicity criteria, version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47(1):13\u201347.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2274_CR14","first-page":"58","volume-title":"UICC-TNM supplement. A commentary on uniform use (ed2)","author":"C Wittekind","year":"2001","unstructured":"Wittekind C, Henson DE, Hutter RPV, et al. UICC-TNM supplement. A commentary on uniform use (ed2). New York: Wiley-Liss Publishers; 2001. p. 58."},{"key":"2274_CR15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"The International Non-Hodgkin\u2019s Lymphoma Factors Project","year":"1993","unstructured":"The International Non-Hodgkin\u2019s Lymphoma Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"key":"2274_CR16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Chesons","year":"2007","unstructured":"Chesons BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphomas. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"2274_CR17","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ijrobp.2006.07.1365","volume":"66","author":"ST Kahn","year":"2006","unstructured":"Kahn ST, Flowers C, Lechowicz MJ, Hollenbach K, Johnstone PA. Value of PET restaging after chemotherapy for non-Hodgkin\u2019s lymphoma: implications for consolidation radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:961\u20135.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2274_CR18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/bjc.1995.364","volume":"72","author":"DG Altman","year":"1995","unstructured":"Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in Cancer Journals. Br J Cancer. 1995;72:511\u20138.","journal-title":"Br J Cancer"},{"key":"2274_CR19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"2274_CR20","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1200\/JCO.2009.22.5896","volume":"27","author":"JD Gundrum","year":"2009","unstructured":"Gundrum JD, Mathiason MA, Moore DB, Go RS. Primary testicular diffuse large B-cell lymphoma: a population based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009;27:5227\u201332.","journal-title":"J Clin Oncol"},{"key":"2274_CR21","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/0360-3016(82)90289-9","volume":"8","author":"SJ Buskirk","year":"1982","unstructured":"Buskirk SJ, Evans RG, Banks PM, O\u2019Connell MJ, Earle JD. Primary lymphoma of the testis. Int J Radiat Oncol Biol Phys. 1982;8:1699\u2013703.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2274_CR22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12185-014-1646-3","volume":"100","author":"K Ichikawa","year":"2014","unstructured":"Ichikawa K, Noguchi M, Koike M, Aritaka N, Sekiguchi Y, Sunami Y, et al. Rituximab plus a CHOP-like regimen, central nervous system prophylaxis, and contralateral testicular irradiation for localized primary testicular diffuse large B-cell lymphoma lead to prolonged progression-free survival. Int J Hematol. 2014;100:370\u20138.","journal-title":"Int J Hematol"},{"key":"2274_CR23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.critrevonc.2007.08.005","volume":"65","author":"U Vitolo","year":"2008","unstructured":"Vitolo U, Ferreri AJ, Zucca E. Primary testicular lymphoma. Crit Rev Oncol Hematol. 2008;65:183\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2274_CR24","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1080\/02841860410002851","volume":"43","author":"S Hasselblom","year":"2004","unstructured":"Hasselblom S, Ridell B, Wedel H, Norrby K, Sender Baum M, Ekman T. Testicular lymphoma, a retrospective, population-based, clinical and immunohistochemical study. Acta Oncol. 2004;43:758\u201365.","journal-title":"Acta Oncol"},{"key":"2274_CR25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000081319","volume":"67","author":"A Avil\u00e9s","year":"2004","unstructured":"Avil\u00e9s A, Neri N, Huerta-Guzm\u00e1n J, P\u00e9rez F, Fern\u00e1ndez R. Testicular lymphoma: organ-specific treatment did not improve outcome. Oncology. 2004;67:211\u20134.","journal-title":"Oncology"},{"key":"2274_CR26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1179\/102453311X13085644680221","volume":"16","author":"B Cao","year":"2011","unstructured":"Cao B, Ji DM, Zhou XY, Zhao TP, Guo Y, Wang ZH, et al. A clinical analysis of primary testicular diffuse large B-cell lymphoma in China. Hematology. 2011;16:291\u20137.","journal-title":"Hematology"},{"key":"2274_CR27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3816\/CLM.2009.n.075","volume":"9","author":"A Aviles","year":"2009","unstructured":"Aviles A, Nambo MJ, Cleto S, Neri N, Huerta-Guzm\u00e1n J. Rituximab and dose-dense chemotherapy in primary testicular lymphoma. Clin Lymphoma Myeloma. 2009;9:386\u20139.","journal-title":"Clin Lymphoma Myeloma"},{"key":"2274_CR28","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3109\/10428191003793358","volume":"51","author":"A Mazloom","year":"2010","unstructured":"Mazloom A, Fowler N, Medeiros LJ, Iyengar P, Horace P, Dabaja BS. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M.D. Anderson Cancer Center experience. Leuk Lymphoma. 2010;51:1217\u201324.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2274_CR29","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2013-10-530659","volume":"123","author":"CY Cheah","year":"2014","unstructured":"Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood. 2014;123(4):486\u201393.","journal-title":"Blood"},{"key":"2274_CR30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3816\/CLM.2001.n.010","volume":"2","author":"C Visco","year":"2000","unstructured":"Visco C, Medeiros LJ, Mesina OM, Rodriguez MA, Hagemeister FB, McLaughlin P, et al. Non-Hodgikin\u2019s lymphoma affecting the testis: Is it curable with doxorubicin-based therapy? Clin Lymphoma. 2000;2:40\u20136.","journal-title":"Clin Lymphoma."},{"issue":"1","key":"2274_CR31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275\u201382 (epub 22 Sep 2003).","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-017-2274-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2274-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2274-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T13:24:26Z","timestamp":1505913866000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-017-2274-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,13]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["2274"],"URL":"https:\/\/doi.org\/10.1007\/s12185-017-2274-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,13]]}}}